Desmoid Tumor Clinical Trial
Official title:
Phase 1 Trial of BC2059 (Tegavivint) in Patients With Unresectable Desmoid Tumor
Phase I, open-label, non-randomized study to evaluate safety of BC2059 administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive.
This study is a phase I, open-label, non-randomized study to evaluate safety of BC2059 administered intravenously to subjects with proven primary or recurrent desmoid tumor that is unresectable and symptomatic or progressive. This study will utilize single patient cohorts for the first two dose levels in order to minimize sub-optimal drug exposures, followed by a conventional 3+3 dose escalation phase to achieve MTD or RP2D determined by pharmacokinetics or biologically relevant activity. Once MTD or RP2D is determined, that dose level cohort will expand to 14 patients enrolled to collect additional safety PK and PD data. If at least 1 patient has clinical benefit, the dose expansion phase will be expanded by a further 11 patients (25 total in at RP2D). The total duration of study for each subject will be dependent upon the safety, tolerability and efficacy of BC2059 ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05561036 -
A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor
|
Phase 3 | |
Completed |
NCT00287846 -
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
|
Phase 1/Phase 2 | |
Recruiting |
NCT06258421 -
Burden of Disease and Living Situation in Desmoid Patients
|
||
Completed |
NCT00030680 -
Radiation Therapy in Treating Patients With Aggressive Fibromatoses
|
Phase 2 | |
Recruiting |
NCT06081400 -
Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting
|
N/A | |
Active, not recruiting |
NCT04871282 -
A Study of AL102 in Patients With Progressing Desmoid Tumors
|
Phase 2/Phase 3 | |
Recruiting |
NCT01567046 -
Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas
|
N/A | |
Completed |
NCT01137916 -
Study to Evaluate Imatinib in Desmoid Tumors
|
Phase 2 | |
Completed |
NCT00002595 -
Toremifene in Treating Patients With Desmoid Tumors
|
Phase 2 | |
Completed |
NCT06195085 -
CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
|
||
Completed |
NCT01286662 -
A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome
|
N/A | |
Completed |
NCT01265030 -
A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis
|
Phase 1/Phase 2 | |
Completed |
NCT00068419 -
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
|
Phase 2 | |
Completed |
NCT04289077 -
Quality of Life of Patients With Desmoid-type Fibromatosis
|
||
Completed |
NCT03190174 -
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00003019 -
Vinblastine and Methotrexate in Treating Children With Desmoid Tumors
|
Phase 2 | |
Recruiting |
NCT05949099 -
Study of Cryoablation and Nirogacestat for Desmoid Tumor
|
Phase 2 | |
Active, not recruiting |
NCT02076906 -
MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors
|
Phase 1 | |
Completed |
NCT00474994 -
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
|
Phase 2 | |
Active, not recruiting |
NCT03785964 -
Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
|
Phase 3 |